Anti-influenza M2e antibody
View Patent ↗Humanized recombinant and monoclonal antibodies specific for the ectodomain of the influenza virus M2 ion channel protein are disclosed. The antibodies of the invention have anti-viral activity and may be useful as anti-viral therapeutics and/or prophylactic/vaccine agents for inhibiting influenza virus replication and for treating individuals infected with influenza.
1. A humanized anti-M2e monoclonal antibody, or antigen-binding fragment thereof, wherein the antibody or the antigen binding fragment thereof specifically binds influenza M2e polypeptide, and wherein the antibody or antigen-binding fragment thereof comprises a light chain variable region of SEQ ID NO: 1 and a heavy chain variable region of SEQ ID NO: 2.
2. The humanized anti-M2e monoclonal antibody of claim 1 , wherein the antibody is a scFv.
3. The humanized anti-M2e monoclonal antibody antigen-binding fragment of claim 1 , wherein the antigen binding fragment is selected from the group consisting of Fab and Fab′.
4. The humanized anti-M2e monoclonal antibody of claim 1 , wherein the antibody is a minibody.
5. The humanized anti-M2e monoclonal antibody of claim 1 , wherein the antibody is an immunoglobulin selected from the group consisting of IgA, IgD, IgE, IgG and IgM.
6. An antibody formulation comprising the antibody according to claim 1 or an antigen binding fragment thereof and a pharmaceutically acceptable carrier.